Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements

Acta Oncologica

Volumn 35, Issue 2, 1996, Pages 141-148

  Glimelius, Bengt ^a   Hoffman, Katarina ^a   Einarsson, Roland ^b   Påhlman, Lars ^a   Graf, Wilhelm ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b BEKI Diagnostics AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0029920275     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098494     Document Type: Article

References (30)

1. Slevin ML, Slubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990; 300: 1458-60.
2. Lavin P, Mittelman A, Douglass H, et al. Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An Eastern Cooperative Oncology Group Report. Cancer 1980; 46: 1536-43.
3. Kemeny N, Braun DW. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenas level, performance status and white blood cell count. Am J Med 1983; 74: 786-94.
4. Edler L, Heim ME, Quintero C, et al. Prognostic factors of advanced colorectal cancer patients. Eur J Cancer Clin Oncol 1986; 22: 1231-7.
5. Graf W, Glimelius B, Påhlman L. et al. Determinants of prognosis in advanced colorectal cancer patients treated with chemotherapy. Eur J Cancer 1991; 27: 1119-23.
6. Graf W, Påhlman L, Bergström R, et al. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur J Cancer 1994; 30: 453-7.
7. Allen-Mersh TG, Kemeny N, Niedzwiecki D, et al. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 1986; 28: 1625-16.
8. Quentmeier A, Schlag P, Hohenberger P, et al. Assessment of serial carcinoembryonic antigen determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy. J Surg Oncol 1989; 40: 112-8.
9. Ward U, Primrose JN, Finan PJ, et al. The use of tumour markers CEA, CA-195, and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993; 67: 1132-5.
10. Kuori M, Pyrhönen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992; 49: 78-85.
11. Zetterberg A, Skern T, Schöber E, et al. Molecular characterization of TPS (Abstract). Tumor Biol 1995; 16: 334.
12. Björklund B. A conceptual approach to tumor antigen in the past and in the future with special reference to TPS. In: Ballesta AM, Torre GC, Bombardieri E, Gion M, Molina R, eds. Updating on tumor markers in tissues and in biological fluids. Torino: Minerva Medica 1993; 651-69.
13. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-41.
14. Glimelius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in symptomatic patients with advanced colorectal cancer. Cancer 1994; 73: 556-62.
15. Glimelius B, Hoffman K, Haglund U, et al. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994; 5: 189-90.
16. Wilke H, Pruesser P, Stahl M, et al. Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. Cancer Chemother Pharmacol 1991; 29: 83-4.
17. Miller AB, Hoogstraten B, Staquet, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
18. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Sequential methotrexate/5-fluorouracil/leucovorin (MFL) is superior to 5-fluorouracil alone in advanced symptomatic colorectal carcinoma: A randomized trial. J Clin Oncol 1989; 7: 1437-46.
19. Glimelius B, Hoffman K, Olafsdottir M, et al. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: A randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989; 25: 829-35.
20. Glimelius B, Graf W, Hoffman K, et al. General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy: A longitudinal study. Acta Oncol 1992; 31: 645-51.
21. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
22. Cox DR. Regression models and life tables. JR Stat Soc 1972; 34: 187-220.
23. Kornek G, Schenk T, Raderer M, et al. Tissue polypeptide specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumors. Br J Cancer 1995; 71: 182-5.
24. Lindmark G, Gerdin B, Påhlman L, et al. Prognostic predictors in colorectal cancer. Dis Colon Rectum 1994; 37: 1219-27.
25. Pasanen PA, Eskelinen M, Partanen K, et al. Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma. Tumour Biol 1994; 15: 52-60.
26. Slesak B, Harlozinska-Szmyrka A, Van Dalen A, et al. Tissue polypeptide antigen specific (TPS) and carcinoembryonic antigen (CEA) levels in cancerous and precancerous lesions in human colon. Oncology Reports 1995; 2: 567-70.
27. Consensus Statement. Cytostatic drug treatment in advanced cancer. MFR, Spri, Stockholm, Nov 1991.
28. Graf W, Glimelius B, Pählman L, et al. The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 1994; 70: 559-63.
29. Moertel CG. Chemotherapy for colorectal cancer. New Engl J Med 1994; 16: 1136-42.
30. Al-Sarraf M, Baker L, Talley R, et al. The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer 1979; 44: 1222-5.